Randomized trial shows B-cell receptor changes predict immune-related adverse events in renal cell carcinoma, suggesting potential biomarkers for monitoring.
Key Points
The study aims to determine if changes in the peripheral B-cell receptor repertoire can predict immune-related adverse events in patients with metastatic renal cell carcinoma undergoing immune checkpoint inhibitor therapy.
Analyzed peripheral B-cell receptor repertoires before and one month after initiating ICI therapy in 24 patients with metastatic renal cell carcinoma.
Profiled BCR complementarity-determining region 3 sequences using next-generation sequencing.